High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. - Wikidata - wikimedia - TriplyDB

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

http://www.wikidata.org/entity/Q33754471

about

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.The blind spot in high-dose tigecycline pharmacokinetics in critically ill patients: membrane adsorption during continuous extracorporeal treatment.Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues.Mechanisms of antimicrobial resistance in Gram-negative bacilli.Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance Convergence of Minds: For Better Patient Outcome in Intensive Care Unit Infections Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.The challenge of antibiotic resistance in haematology patients.Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report.Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.Diphtheroids-Important Nosocomial Pathogens.Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited.Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.Retrospective analysis of tigecycline shows that it may be an option for children with severe infections.A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.Task force on management and prevention of Acinetobacter baumannii infections in the ICU.Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline.Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii.Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock.

P2860

Q26739860-055206A5-CE41-4768-967C-F9213430E431 Q26799580-92A7F53E-7495-4703-B185-E8618C6E04DB Q28082546-79D79899-39BB-4225-A3E6-A6B88FD7573E Q33822682-42BA16E0-4AD2-411E-BB6E-A1677875362D Q35021183-FA51BB65-7B9C-408D-823E-60B955D2C3C4 Q35778366-9BFCBC9C-A89B-4094-88F3-92673CCBBD87 Q35935319-748FE06A-06BA-4DD6-BEDA-5BCA000FF566 Q36035161-049DC103-4D47-481D-AD27-166B77A96094 Q36076066-555B8E27-64B2-459C-8B79-724A0ADB47A1 Q36344076-421C11A9-5C2F-4F1F-92E7-D78543EC6D31 Q36887811-2DEC8B19-853A-428B-9DC9-F5064730FD8B Q37146405-25B531D5-5B67-4585-A33D-F923D6491D41 Q37511815-6BB18252-FCDA-432E-94C8-496607FFD947 Q38384662-09824810-357B-4CDB-BF1C-9A02B6858E3B Q38416932-E6491E2C-686E-42AA-9F20-718B1191CD2E Q38613929-A545F11D-F221-4F19-9FF9-563D0FA5B9DC Q38783940-A684C5EE-D5CE-4304-B43C-88A803CECC07 Q38918458-1FC3348F-74A6-40E3-97F4-0C6ACD26669C Q38944862-47C12D0E-7817-4FCF-9843-5DC56D0D7439 Q39012881-CE6C6A0B-FCE6-4F4C-8E38-6B912EB399E4 Q39016281-F7F2A870-A7DF-4593-93F2-EF9C46CCBDE1 Q39222597-2DF34142-EFEE-44E8-8824-BB54550AD870 Q40144073-D1C93765-725F-4421-8D98-5047297CB597 Q40146757-CD2F5362-5799-431F-B607-C4A316CCFEF8 Q40175198-60BC0A63-1DB3-4EAB-B5B3-37CFEC92C510 Q40329490-36DB46D1-BDB4-4AF6-9392-CA9C85A6DE85 Q40423903-5DAB0B7E-B542-427B-9662-753DD11DB1E5 Q40533542-08F8DE9F-93E4-403A-8CF1-8F12DB05AFA4 Q40624454-A26607E6-6649-49C3-B6D1-F7AC35A2977F Q40809870-78FD80AD-3854-4BEA-881D-8E09482C5140 Q40965515-00147536-B9EC-4873-B8C8-1DE1F66E8D76 Q40976615-8C106B2B-1F8C-415B-9548-63919841B0A8 Q41004466-A244E7E5-DA18-48B1-82CA-6A876E3C28A8 Q42335968-63795368-A021-4D69-A3F7-C8660137C3C5 Q42369290-0CE29105-AD14-4CB4-8015-18F4E44DE7B3 Q47143645-AAB952BB-F9A4-40A0-9C12-EABAC6152995 Q47661746-C880A04E-950B-487F-8031-81B84B712D05 Q48197188-E376B5E0-2775-43F8-8737-DF043F7B513F Q49711959-5B64F123-3240-4FA2-8FB3-27AD7D494C87 Q49874670-5A2D3758-5AC8-4EB9-A169-CEE67E1288D4

P2860

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

http://www.wikidata.org/entity/Q33754471

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@ast

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@en

type

label

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@ast

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@en

prefLabel

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@ast

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@en

P1433

Q33754471-5E0ABF4D-C359-4787-8B90-B1F3402C030E

P1476

Q33754471-6695509D-6A1D-4E70-B0AA-385C08C0484E

P2093

Q33754471-1C1ADE3D-32D8-4149-B2B5-DBB2D601A71A

Q33754471-35D2A20D-A0D9-4F93-8917-D77231E6A315

Q33754471-5D32995B-03ED-401C-8C4A-8EB26AED3E93

Q33754471-924A1639-426F-4409-B34D-3ED7A4ED61B4

Q33754471-CB1B9B30-60C7-4DF7-B3D3-7DFEF3465F86

Q33754471-CC79B02D-C295-44EC-866E-E37AE6593A09

P2860

Q33754471-08D3CF2A-A102-4E34-83CF-75457BBE06B2

Q33754471-0BB7C8D3-642B-44DB-908A-FD4F28E962A2

Q33754471-0C63CB44-C365-4AB8-BAA1-442E9B241593

Q33754471-14D58A53-2D01-4E1D-BDC0-1A51F9E7EE56

Q33754471-16D049C1-E234-4891-AF35-154624A10759

Q33754471-20D4542D-BED1-4D10-8445-8BA266FB4BAE

Q33754471-274890E2-1841-4FE6-BCB2-461FCC2B83BD

Q33754471-2D4F44F7-5E52-447C-97DF-7A6E6E0B9735

Q33754471-5300FC9A-5F26-4520-96C5-57E4326DC263

Q33754471-7CAE92D7-BBEF-41BC-B54B-D896AB9198CA

P2888

Q33754471-C5EB5AD9-19CB-4FDC-A935-2CE16A7509BA

P304

Q33754471-0F156456-DF8B-4EF1-A447-C0C6C4B58258

P31

Q33754471-551F4A51-8FE6-4958-AA70-CDCEE556F7BC

P356

Q33754471-B5459D9A-2B11-4B72-82CB-0D2F74731A90

P433

Q33754471-D6E2E54B-3481-4199-ADD5-F20BA7490A8E

P478

Q33754471-D2C38C7E-400A-4842-826F-CED0D674BD19

P50

Q33754471-76490A57-21EA-452C-9A1A-CAEED878F582

Q33754471-83905477-7590-4655-A664-EE159B2A8766

Q33754471-9AED095B-CE99-41DD-970A-AC034DF9EA4F

P577

Q33754471-B4C7A9DD-98EB-43E3-A224-6BF469F83EF0

P5875

Q33754471-59F054D3-9E09-4A72-824B-9701F7192DB7

P6179

Q33754471-B6BD937F-49E8-43D8-BFD6-504DA0B05D81

P698

Q33754471-85662241-1E67-4B1C-A461-408D2AD0FF98

P921

Q33754471-4C79B6D7-4F31-45AA-AFCD-8E544E43B874

P932

Q33754471-794EA4B3-F1BA-47D5-A87F-646B2FFB8CEC

P356

P1433

P1476

High dose tigecycline in criti ...... multidrug-resistant bacteria.

@en

P2093

Gennaro De Pascale

http://www.w3.org/2001/XMLSchema#string

Giuseppe Bello

http://www.w3.org/2001/XMLSchema#string

Mario Tumbarello

http://www.w3.org/2001/XMLSchema#string

Riccardo Maviglia

http://www.w3.org/2001/XMLSchema#string

Teresa Spanu

http://www.w3.org/2001/XMLSchema#string

Valentina Bernini

http://www.w3.org/2001/XMLSchema#string

P2860

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America

Tigecycline use in serious nosocomial infections: a drug use evaluation.

Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.

Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens

Tigecycline: a critical analysis.

Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

P2888

P304

R90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC13858

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Antonelli

Mariano Alberto Pennisi

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262777773

http://www.w3.org/2001/XMLSchema#string

P6179

1016969903

http://www.w3.org/2001/XMLSchema#string

P698

24887101

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

4057423

http://www.w3.org/2001/XMLSchema#string